Frontiers of Medicine

, Volume 11, Issue 2, pp 229–238 | Cite as

Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Yinjun Lou
  • Yafang Ma
  • Chenyin Li
  • Sansan Suo
  • Hongyan Tong
  • Wenbin Qian
  • Wenyuan Mai
  • Haitao Meng
  • Wenjuan Yu
  • Liping Mao
  • Juyin Wei
  • Weilei Xu
  • Jie Jin
Research Article

Abstract

A CALLG2008 protocol was developed by the Chinese Acute Lymphoblastic Leukemia Cooperative Group for adult acute lymphoblastic leukemia (ALL). We retrospectively analyzed 153 newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL enrolled into imatinib (400 mg/d) plus CALLG2008 regimen between 2009 and 2015. The median age was 40 years (range, 18–68 years), with 81 (52.3%) males. The overall hematologic complete remission (CR) rate was 96.7% after induction. With a median follow-up of 24.2 months, the estimated 3-year overall survival (OS) and event-free survival (EFS) rates were 49.5%(95%confidence interval (CI): 38.5%–59.5%) and 49.2% (95% CI: 38.3%–59.2%), respectively. Fifty-eight (36 with haploidentical donor) patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first CR. Among the patients in CR1 after induction, both the 3-year OS and EFS were significantly better in the allo-HSCT group than in the without allo-HSCT group (73.2%, 95% CI: 58.3%–83.5% vs. 22.2%, 95% CI: 8.7%–39.6% and 66.5%, 95% CI: 50.7%–78.2% vs. 16.1%, 95% CI: 5.1%–32.7%, respectively). Multivariate analysis showed that allo-HSCT and achievement of major molecular response were associated with favorable OS or EFS independently. Interestingly, in the allo-HSCT cohort, the donor type (haploidentical versus matched donors) had no significant impact on EFS or OS. All these results suggested that imatinib plus CALLG2008 was an effective protocol for Ph-positive ALL. Haploidentical donors can also be a reasonable alternative expedient donor pool.

Keywords

Philadelphia chromosome acute lymphoblastic leukemia imatinib CALLG2008 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

We thank all the medical and nursing staff working in the Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University for providing patient information. This work was supported in part by the National High Technology Research and Development Program of China (863 Program) (No. 2012AA02A505), Leukemia Research Innovative Team of Zhejiang Province (No. 2011R50015), and Medical and Health Science Project of Zhejiang Province (No. 2015RCB012).

References

  1. 1.
    Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Insti-tute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/ Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109(8): 3189–3197CrossRefPubMedGoogle Scholar
  2. 2.
    Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, Di Nardo C, Wierda W, Jeanis V, O’Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 2015; 16(15): 1547–1555CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ravandi F, O’Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomepositive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116(12): 2070–2077CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O’Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2015; 100(5): 653–661CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28(22): 3644–3652CrossRefPubMedGoogle Scholar
  6. 6.
    Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, Mc Millan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH. UKALLXII/ ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014; 123(6): 843–850CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G, Baccarani M; GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118(25): 6521–6528CrossRefPubMedGoogle Scholar
  8. 8.
    Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 2015; 126(6): 746–756CrossRefPubMedGoogle Scholar
  9. 9.
    Chiaretti S, Foa R. Management of adult Ph-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2015; 2015: 406–413PubMedGoogle Scholar
  10. 10.
    Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(suppl 5): v69–v82PubMedGoogle Scholar
  11. 11.
    Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2010; 116(18): 3409–3417CrossRefPubMedGoogle Scholar
  12. 12.
    Ribera JM. Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma 2013; 54(1): 21–27CrossRefPubMedGoogle Scholar
  13. 13.
    Mi JQ, Wang X, Yao Y, Lu HJ, Jiang XX, Zhou JF, Wang JH, Jiao B, Shen SH, Tang JY, Gu LJ, Jiang H, Ma LY, Hao SG, Chen FY, Xiong SM, Shen ZX, Chen Z, Chen B, Chen SJ. Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Leukemia 2012; 26(7): 1507–1516CrossRefPubMedGoogle Scholar
  14. 14.
    Wang JX. A Chinese expert panel consensus on diagnosis and treatment of adult acute lymphoblastic leukemia (Chinese Society of Hematology, Chinese Medical Association; Society of Hematological Malignancies Chinese Anti-Cancer Association). Chin J Hematol (Zhonghua Xue Ye Xue Za Zhi) 2012; 33(9): 789–792 (in Chinese)Google Scholar
  15. 15.
    Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Yu X, Cai Z, Lin M, Huang H. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 2014; 124(17): 2735–2743CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, Wu MQ, Wu DP, Huang XJ. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res 2016; 22(14): 3467–3476CrossRefPubMedGoogle Scholar
  17. 17.
    Liu KY, Huang XJ. The consensus of allogeneic hematopoietic transplantation for hematological diseases in China (2014)–indication, conditioning regimen and donor selection (Chinese Society of Hematology, Chinese Medical Association). Chin J Hematol (Zhonghua Xue Ye Xue Za Zhi) 2014; 35(8): 775–780 (in Chinese)Google Scholar
  18. 18.
    Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) — a Europe against cancer program. Leukemia 2003; 17(12): 2474–2486CrossRefPubMedGoogle Scholar
  19. 19.
    Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lhéritier V, Chevret S, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 2015; 125(24): 3711–3719CrossRefPubMedGoogle Scholar
  20. 20.
    Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102(1): 276–283CrossRefPubMedGoogle Scholar
  21. 21.
    Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, Falini B, Ronco F, Ferrara F, De Fabritiis P, Luppi M, La Nasa G, Tedeschi A, Califano C, Fanin R, Dore F, Mandelli F, Meloni G, Foà R. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica 2016; 101(12): 1544–1552CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foà R, Baccarani M, Mandelli F. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109(9): 3676–3678CrossRefPubMedGoogle Scholar
  23. 23.
    Gao L, Zhang C, Gao L, Liu Y, Su Y, Wang S, Li B, Yang T, Yuan Z, Zhang X. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China. J Hematol Oncol 2015; 8(1): 90CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen H, Liu KY, Xu LP, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Huang XJ. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2015; 21(6): 1110–1116CrossRefPubMedGoogle Scholar
  25. 25.
    Zhou J, Zhou HX, Zhang R, Wu DP. Efficacy analysis of haploidentical allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Exp Hematol (Zhongguo Shi Yan Xue Ye Xue Za Zhi) 2014; 22(6): 1678–1683 (in Chinese)Google Scholar
  26. 26.
    Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, Di Persio J, De Angelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369(19): 1783–1796CrossRefPubMedGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Yinjun Lou
    • 1
    • 2
  • Yafang Ma
    • 1
  • Chenyin Li
    • 1
  • Sansan Suo
    • 1
  • Hongyan Tong
    • 1
  • Wenbin Qian
    • 1
  • Wenyuan Mai
    • 1
  • Haitao Meng
    • 1
  • Wenjuan Yu
    • 1
  • Liping Mao
    • 1
  • Juyin Wei
    • 1
  • Weilei Xu
    • 1
  • Jie Jin
    • 1
    • 2
  1. 1.Institute of Hematology, Department of Hematology, the First Affiliated Hospital, College of MedicineZhejiang UniversityHangzhouChina
  2. 2.Key Laboratory of Hematopoietic MalignanciesZhejiang Province, HangzhouChina

Personalised recommendations